Stryker Corporation $SYK Shares Acquired by Bradley Foster & Sargent Inc. CT

Bradley Foster & Sargent Inc. CT increased its holdings in Stryker Corporation (NYSE:SYK) by 3.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 90,342 shares of the medical technology company’s stock after acquiring an additional 3,371 shares during the quarter. Bradley Foster & Sargent Inc. CT’s holdings in Stryker were worth $33,397,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Norges Bank acquired a new stake in shares of Stryker during the second quarter worth about $1,882,173,000. Alliancebernstein L.P. lifted its position in Stryker by 307.6% during the 2nd quarter. Alliancebernstein L.P. now owns 5,596,508 shares of the medical technology company’s stock worth $2,214,146,000 after acquiring an additional 4,223,366 shares during the period. Corient Private Wealth LLC grew its stake in shares of Stryker by 104.4% in the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after purchasing an additional 1,146,998 shares during the last quarter. ABN AMRO Bank N.V. acquired a new position in shares of Stryker in the second quarter valued at approximately $191,047,000. Finally, Vanguard Group Inc. raised its stake in shares of Stryker by 1.3% during the second quarter. Vanguard Group Inc. now owns 33,500,571 shares of the medical technology company’s stock worth $13,253,831,000 after purchasing an additional 440,607 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 250,000 shares of Stryker stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the completion of the sale, the director owned 2,457,331 shares of the company’s stock, valued at $891,814,566.52. The trade was a 9.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 5.20% of the stock is currently owned by corporate insiders.

Stryker Trading Down 0.8%

Stryker stock opened at $381.84 on Wednesday. The stock has a 50-day moving average price of $361.24 and a 200 day moving average price of $368.91. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $404.87. The stock has a market cap of $146.13 billion, a PE ratio of 45.46, a P/E/G ratio of 2.25 and a beta of 0.87. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.40 by $0.07. The company had revenue of $7.17 billion for the quarter, compared to analysts’ expectations of $7.12 billion. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The firm’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same period last year, the company earned $4.01 EPS. Equities research analysts predict that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be issued a $0.88 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 annualized dividend and a yield of 0.9%. Stryker’s payout ratio is 41.90%.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. Barclays reissued an “overweight” rating and issued a $469.00 price objective on shares of Stryker in a research note on Monday, February 2nd. Wells Fargo & Company increased their price target on shares of Stryker from $452.00 to $456.00 and gave the stock an “overweight” rating in a report on Friday, November 14th. UBS Group raised their price objective on shares of Stryker from $386.00 to $400.00 and gave the company a “neutral” rating in a research report on Tuesday. Citigroup reissued a “market outperform” rating on shares of Stryker in a research note on Friday, January 30th. Finally, Raymond James Financial upgraded Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 price target on the stock in a research note on Tuesday, January 6th. Thirteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $426.47.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.